Jeni, 35, from Santa Clarita, CA takes a biosimilar medicine for her pancolitis.

Jeni Got Her Life Back, Thanks to a Biosimilar

In 2019, Jeni Doerr finally received a diagnosis for her recent illnesses – pancolitis. Doerr, 35, from Newhall, CA, is featured in AAM’s recently released 2020 Generic Drug & Biosimilars Access & Savings in the U.S. report.

In a suburb of Santa Clarita, California, Jeni recently went back to school to become a medical coder (someone who helps doctors and insurance companies speak the same language), and when she is not online learning she is enjoying everything the state has to offer—hiking, rock climbing and mountain biking with her dog Sally. “If you take me outside, I’m a happy girl,” she says. “Illness changed everything.” “

Every time I went to the bathroom,” she recalls, “I would lose blood and I couldn’t eat anything. I became anemic, and after my symptoms got even worse, I finally went to the ER, where I received a colonoscopy and was diagnosed with pancolitis. I felt like I had lost everything.” But once the doctor prescribed a biosimilar, Jeni says, “It was like flipping a light switch. Biosimilars truly gave me my life back!”

View Jeni's Story


Related Resources

FDA-approved biosimilars have the potential to provide 1.2 million patients access to treatments for rheumatoid arthritis, Crohn’s disease, cancer and other chronic conditions, at a lower cost. Over the next ten years, biosimilars could save the entire U.S. health care system $54 billion. Find out more about how biosimilars truly benefit everyone in this infographic from AAM's Biosimilars Council.

Originally published on the Biosimilars Council website.

View Jeni and other patient stories in the 2021 Voices of Access report.


Erica Klinger—Senior Director, Marketing

By Erica Klinger, Senior Director, Marketing




Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.